Japan's PMDA Supports Q4 2026 Submission for BioCardia's CardiAMP Therapy
BCDA is trading near its 52-week low of $0.84 (12% above the low) on light trading volume (0.3× avg).
Summary
Japan's PMDA (Pharmaceuticals and Medical Devices Agency) has indicated support for BioCardia's regulatory submission for its CardiAMP cell therapy for ischemic HFrEF. The company plans to submit in Q4 2026, with an anticipated seven-month review timeline. This follows a positive PMDA consultation announced on April 20th and an 8-K filed earlier today confirming the same. This is a crucial step forward for BioCardia's lead product in a significant market, potentially offering a path to future revenue for a financially distressed company. The PMDA's support and a clear submission timeline provide a tangible milestone. The actual submission in Q4 2026 and the subsequent seven-month review period will be key.
At the time of this announcement, BCDA was trading at $0.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.2M. The 52-week trading range was $0.84 to $2.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.